Cidara Therapeutics, Inc. (20D.F)

0,4780 0,0000 (0,00%) Ab 08:55PM CEST. Markt geöffnet.

Cidara Therapeutics, Inc.

6310 Nancy Ridge Drive
Suite 101
San Diego, CA 92121
United States
858 752 6170
https://www.cidara.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 69

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jeffrey L. Stein Ph.D.	President, CEO & Executive Director	564,06k	N/A	1955
Dr. Taylor Sandison	Chief Medical Officer	464,36k	N/A	1972
Dr. Kevin M. Forrest Ph.D.	Founder and Chief Strategy Officer	311,43k	N/A	1977
Ms. Allison Lewis CCP, SPHR	Senior Vice President of People & Culture	N/A	N/A	N/A
Dr. Leslie Tari Ph.D.	Chief Scientific Officer	789,61k	N/A	1967
Ms. Laura A. Navalta	Senior Vice President of Clinical Operations	N/A	N/A	N/A
Dr. Nicole Davarpanah J.D., M.D.	Senior VP of Translational Research & Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Corporate Governance

Cidara Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 6, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.